Celltrion’s ‘Truxima’ reaches 30% market share in Europe only in 3 months of launch

‘Truxima,’ an antibody biosimilar launched by Celltrion Healthcare for the 2^nd time in Europe, seems to rapidly grow in the European market.

Celltrion Healthcare announced on the 1^st that ‘Truxima,’ an antibody biosimilar developed by Celltrion for the treatment of blood cancer, exceeded a 30% market share in some of the European countries, such as the U.K. and Netherlands, only in 3 months of...